**Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients**

Eiji Oki, MD1\*, Eiji Shinto, MD2, Mototsugu Shimokawa, PhD3, Shigeki Yamaguchi, MD4, Megumi Ishiguro, MD5, Seiji Hasegawa, MD6, Yasumasa Takii, MD7, Hideyuki Ishida, MD8, Tetsuya Kusumoto, MD9, Masaru Morita, MD10, Naohiro Tomita, MD11, Manabu Shiozawa, MD12, Masafumi Tanaka, MD13, Heita Ozawa, MD14, Yojiro Hashiguchi, MD15, Shinobu Ohnuma, MD16, Sachiyo Tada, PhD17, Tomoko Matsushima, PhD17, and Kazuo Hase, MD2

1Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

2Department of Surgery, National Defense Medical College, Tokorozawa, Japan

3Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

4Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan

5Department of Translational Oncology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan

6Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

7Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan

8Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

9Department of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

10Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

11Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

12Colorectal Surgery Division, Kanagawa Cancer Center, Yokohama, Japan

13Coloproctology Center, Takano Hospital, Kumamoto, Japan

14Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan

15Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan

16Department of Surgery, Tohoku University Hospital, Sendai, Japan

17LS Business, Sysmex Corporation, Kobe, Japan

\***Corresponding author:** Dr. Eiji Oki

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University

3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Phone number: +81-92-642-5464

Email: okieiji@surg2.med.kyushu-u.ac.jp

**Supplementary Table S1.** Patient background in each subtype

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Factors** | | **MSI-like (N=52) n (%)** | **CIN-like (N=78) n (%)** | **Stromal (N=60) n(%)** | **Total (N=190) n(%)** | **P value** |
| Sex | Male | 28 (53.8) | 39 (50.0) | 31 (51.7) | 98 (51.6) | p=0.9116 |
| Female | 24 (46.2) | 39 (50.0) | 29 (48.3) | 92 (48.4) |
| Age | <70 | 37 (71.2) | 65 (83.3) | 44 (73.3) | 146 (76.8) | p=0.2011 |
| ≥70 | 15 (28.8) | 13 (16.7) | 16 (26.7) | 44 (23.2) |
| CEA | <ULN | 33 (63.5) | 51 (65.4) | 29 (48.3) | 113 (59.5) | p=0.1847 |
| ≥ULN | 14 (26.9) | 17 (21.8) | 20 (33.3) | 51 (26.8) |
| Unknown | 5 (9.6) | 10 (12.8) | 11 (18.3) | 26 (13.7) |
| Tumor location | Right side | 26 (50.0) | 18 (23.1) | 20 (33.3) | 64 (33.7) | p=0.0063 |
|  | Left side | 26 (50.0) | 60 (76.9) | 40 (66.7) | 126 (66.3) |  |
| T stage | T1-T3 | 30 (57.7) | 50 (64.1) | 32 (53.3) | 112 (58.9) | p=0.4335 |
|  | T4 | 22 (42.3) | 28 (35.9) | 28 (46.7) | 78 (41.1) |  |
| Histology | Non muc | 46 (88.5) | 78 (100.0) | 58 (96.7) | 182 (95.8) | p=0.0036 |
| muc | 6 (11.5) | 0 (0.0) | 2 (3.3) | 8 (4.2) |
| Tumor grade | por & muc | 11 (21.2) | 2 (2.6) | 4 (6.7) | 17 (8.9) | p=0.0010 |
| tub | 41 (78.8) | 76 (97.4) | 56 (93.3) | 173 (91.1) |
| Lymphatic invasion | Negative | 14 (26.9) | 28 (35.9) | 13 (21.7) | 55 (28.9) | p=0.1754 |
| Positive | 38 (73.1) | 50 (64.1) | 47 (78.3) | 135 (71.1) |
| Vascular invasion | Negative | 14 (26.9) | 26 (33.3) | 11 (18.3) | 51 (26.8) | p=0.1433 |
| Positive | 38 (73.1) | 52 (66.7) | 49 (89.7) | 139 (73.2) |
| N stage | N1 | 13 (25.0) | 39 (50.0) | 23 (38.3) | 75 (39.5) | p=0.0021 |
| N2 | 34 (65.4) | 39 (50.0) | 31 (51.7) | 104 (54.7) |
| N3 | 5 (9.6) | 0 (0.0) | 6 (10.0) | 11 (5.8) |
| Number of resected lymph nodes | <12 | 3 (5.8) | 11 (14.1) | 6 (10.0) | 20 (10.5) | p=0.3125 |
| ≥12 | 49 (94.2) | 67 (85.9) | 54 (90.0) | 170 (89.5) |
| Adjuvant chemotherapy | With oxaliplatin | 25 (48.1) | 42 (53.8) | 28 (46.7) | 95 (50.0) | p=0.6686 |
| Without oxaliplatin | 27 (51.9) | 36 (46.2) | 32 (53.3) | 95 (50.0) |

CEA – carcinoembryonic antigen, ULN – upper limit of normal, muc – mucinous, por & muc - poorly differentiated and mucinous adenocarcinoma, tub - tubular adenocarcinoma



**Supplementary Figure S1.** Five-year relapse-free survival (RFS) curves in 55-gene classifier (55GC) subtypes according to adjuvant chemotherapy received [blue: microsatellite instability (MSI)-like; red: chromosomal instability (CIN)-like; green: stromal].



**Supplementary Figure S2.** Subgroup analysis